Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
temuterkib (LY3214996)
i
Other names:
LY3214996, LY 3214996, LY-3214996
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3)
News
Trials
Company:
Eli Lilly
Drug class:
ERK2 inhibitor, ERK1 inhibitor
Related drugs:
‹
BVD-523 (17)
BAY86-9766 (16)
ERAS-007 (13)
VTX-11e (5)
JSI-1187 (4)
ASTX029 (4)
LTT462 (3)
AEZS 136 (1)
D3S-002 (0)
HH2710 (0)
MK-8353 (0)
ATG-017 (0)
BVD-523 (17)
BAY86-9766 (16)
ERAS-007 (13)
VTX-11e (5)
JSI-1187 (4)
ASTX029 (4)
LTT462 (3)
AEZS 136 (1)
D3S-002 (0)
HH2710 (0)
MK-8353 (0)
ATG-017 (0)
›
Associations
(3)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Targeted Pathway Inhibition in Patients With Pancreatic Cancer (NCT04005690)
Phase 1
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Recruiting
Phase 1
OHSU Knight Cancer Institute
Recruiting
Last update posted :
02/13/2025
Initiation :
08/01/2019
Primary completion :
06/01/2026
Completion :
02/01/2028
UGT1A1 • CD4
|
UGT1A1*1*1
|
Lynparza (olaparib) • Cotellic (cobimetinib) • Imjudo (tremelimumab-actl) • onvansertib (PCM-075) • azenosertib (ZN-c3) • saruparib (AZD5305) • temuterkib (LY3214996)
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (KEYNOTE E27) (NCT04956640)
Phase 1/2
Eli Lilly and Company
Eli Lilly and Company
Recruiting
Phase 1/2
Eli Lilly and Company
Recruiting
Last update posted :
01/28/2025
Initiation :
07/19/2021
Primary completion :
06/01/2026
Completion :
06/01/2026
KRAS
|
KRAS mutation • KRAS G12C • KRAS G12
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer (NCT04616183)
Phase 1/2
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Active, not recruiting
Phase 1/2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
05/30/2024
Initiation :
12/02/2020
Primary completion :
12/31/2025
Completion :
12/31/2025
KRAS • BRAF • MAP2K1
|
Erbitux (cetuximab) • Verzenio (abemaciclib) • temuterkib (LY3214996) • Datalai (cetuximab biosimilar)
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients (NCT04391595)
Phase 1
Nader Sanai
Nader Sanai
Recruiting
Phase 1
Nader Sanai
Recruiting
Last update posted :
03/27/2024
Initiation :
07/08/2020
Primary completion :
12/01/2024
Completion :
02/01/2025
CDKN2A • CDK4 • CDKN2B
|
CDK4 amplification
|
Verzenio (abemaciclib) • temuterkib (LY3214996)
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer (NCT02857270)
Phase 1
Eli Lilly and Company
Eli Lilly and Company
Completed
Phase 1
Eli Lilly and Company
Completed
Last update posted :
11/22/2022
Initiation :
09/29/2016
Primary completion :
02/10/2021
Completion :
10/24/2022
BRAF • NRAS
|
BRAF V600E • NRAS mutation • BRAF V600 • RAS mutation
|
Erbitux (cetuximab) • gemcitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Braftovi (encorafenib) • temuterkib (LY3214996) • midazolam hydrochloride
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) (NCT04916236)
Phase 1
The Netherlands Cancer Institute
The Netherlands Cancer Institute
Recruiting
Phase 1
The Netherlands Cancer Institute
Recruiting
Last update posted :
06/03/2022
Initiation :
03/31/2022
Primary completion :
01/31/2024
Completion :
07/01/2024
EGFR • KRAS • PIK3CA • MET • PTEN • HRAS
|
vociprotafib (RMC-4630) • temuterkib (LY3214996)
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies (NCT04043845)
Phase 1
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Withdrawn
Phase 1
Dana-Farber Cancer Institute
Withdrawn
Last update posted :
02/05/2020
Initiation :
02/03/2020
Primary completion :
02/03/2020
Completion :
02/03/2020
PLCG2
|
Imbruvica (ibrutinib) • temuterkib (LY3214996)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login